GEOMed360 / Winning the Answer / The operating framework

Chapter 05

The GEO operating framework: tiers, lifecycle, and the PICO standard

GEO cannot be run as a website project. It requires a prioritization logic across content the company controls to different degrees, a sequencing logic across the product lifecycle, and a content standard that regulatory and medical functions can pre-approve. This chapter sets out all three.

5.1 The three-tier content architecture

All content that shapes AI answers about a medicine can be assigned to one of three tiers, defined by authority and control. The tiers are not equally important, and they are not managed the same way.

Exhibit 7
Three tiers of AI-relevant content — and where control actually lies
Diagram of three content tiers: Tier 1 truth engine (regulatory labels, registries, publications, guidelines), Tier 2 narrative hubs (owned websites and portals), Tier 3 amplification layer (social, forums, news)
Source: GEOMed360 framework, synthesized from portfolio audit findings and published GEO research.
  • Tier 1 — the truth engine. Regulatory labels and their public repositories, trial registries, peer-reviewed publications, and clinical guidelines. These carry the highest machine-assigned authority and anchor every downstream answer. The manufacturer shares control with regulators, journals, and societies — but controls completeness, currency, open-access status, and the structured summaries that surround them. Goal: every Tier 1 asset complete, current, canonical, and machine-readable.
  • Tier 2 — narrative hubs. Corporate and brand websites, press releases, medical-information content, and HCP portals. Fully owned, fully controllable — and, in audits, dramatically under-cited relative to their accuracy. Goal: convert this estate from promotional prose to structured clinical data with semantic architecture, so it becomes the connective tissue linking Tier 1 evidence to user questions.
  • Tier 3 — the amplification layer. Social platforms, patient forums, independent clinician commentary, and news coverage. Uncontrolled and unsuppressible. Goal: systematic monitoring with defined escalation triggers — and the strategic understanding that Tier 3 errors are corrected upstream, by strengthening Tiers 1 and 2, not by chasing individual posts. Audit evidence supports the cascade: models resolve conflicts between tiers in favour of higher-authority sources when those sources are retrievable.19

5.2 Sequencing across the product lifecycle

GEO priorities shift predictably as an asset moves from clinical development to post-launch maturity. The heat map below summarizes where effort concentrates in each phase; three dynamics explain it.

Exhibit 8
Where GEO effort concentrates across the lifecycle
Heat map of GEO workstream intensity across four lifecycle phases: clinical development, pre-launch, launch, and post-launch
Source: GEOMed360 framework based on portfolio audit findings across clinical-development, pre-launch, launch, and post-launch assets.
  • Clinical development sets the baseline narrative. Trial registrations, early publications, and encyclopedic sources indexed in this phase become the training-data substrate every later answer builds on. Registry completeness and structured protocol summaries are cheap now and expensive to retrofit. Errors seeded here — a vague endpoint description, an outdated registry entry — persist for years.19
  • Launch is a canonicalization event. The approved label becomes the single most-cited source across models; the launch window determines whether the canonical label URL, the regulatory repository entry, the approval press release, and the third-party aggregator entries all align. Getting the launch-week content architecture right is the highest-leverage GEO intervention in the entire lifecycle.19
  • Post-launch is version management. Every label supplement is a full GEO re-launch: the updated version must become dominantly indexed, explicitly marked as superseding, and cascaded to every owned and managed third-party surface within days. Real-world evidence and meta-analyses gain citation weight over time and shape comparative narratives; whoever publishes the accessible synthesis frames the class.19

5.3 The PICO standard: pre-approvable structure for machine-readable claims

The single most transferable content practice observed across successful remediations is the conversion of narrative efficacy claims into PICO-structured statements: Population, Intervention, Comparator, Outcome — with explicit statistics, confidence intervals, data-cut dates, and co-located safety context. The format is native to evidence-based medicine, which is precisely what makes it powerful: medical, legal, and regulatory reviewers can pre-approve a PICO template once and apply it across assets, converting GEO from a per-asset negotiation into a governed production standard.16,17

A before-and-after illustrates the mechanism. The promotional sentence "Patients experienced significant and rapid improvement in disease control" gives a retrieval system nothing: no population, no number, no comparator, no timeframe. Its PICO conversion — "In adults with [biomarker-defined disease] (Population), [therapy, dose, schedule] (Intervention) versus [comparator] (Comparator) achieved an objective response rate of X percent (95% CI: a–b) at the pre-specified analysis, data cut [date] (Outcome); the most common grade ≥3 adverse events were [events], and no dose adjustment is required for mild renal impairment" — is retrievable, quotable, attributable, and safe to reuse. Every element maps directly to the interventions the peer-reviewed GEO evidence found most effective: statistics, quotable statements, and explicit sourcing.10

References cited in this chapter

Numbering follows the full GEOMed360 whitepaper, Winning the Answer.

  1. 10.Aggarwal, P., Murahari, V., Rajpurohit, T., Kalyan, A., Narasimhan, K., & Deshpande, A., 'GEO: Generative Engine Optimization,' Proceedings of the 30th ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD 2024); GEO-bench benchmark of 10,000 queries across nine domains; visibility improvements up to 40% overall and up to 115% for lower-ranked content. arXiv:2311.09735
  2. 16.MM+M (Medical Marketing and Media), 'Real Chemistry launches new HealthGEO tool,' August 2025.
  3. 17.Indegene, 'GEO vs AEO vs LLMO: The New Search Optimization Trinity for Pharma,' December 2025.
  4. 19.GEOMed360 analysis: multi-model, dual-persona audit programme across a pharmaceutical portfolio spanning oncology, cardiometabolic disease, and interstitial lung disease, 2025–2026 (see the methodology note in Measuring what matters).